Disease prognosis was compared in recurrent and/or metastatic ERBB2-positive breast cancer patients treated with neratinib plus paclitaxel vs. trastuzumab plus paclitaxel as the first line of treatment. The gene discussed is ERBB2; the disease is breast carcinoma.